Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | JAK1 | P23458 | 6/20 | 0.36 |
| ▸ | TYK2 | P29597 | 6/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184103 | 0.82 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL99248 | 0.79 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL15970561 | 0.74 | JAK2 (0.33) | JAK2JAK1TYK2JAK3ACVR1 | |
| SCHEMBL101162 | 0.74 | GRM4 (0.34) | GRM4 | |
| SCHEMBL15970035 | 0.74 | CHUK (0.34) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL18088603 | 0.72 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL18088604 | 0.72 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL100496 | 0.71 | LMNA (0.32) | — | |
| SCHEMBL15970036 | 0.71 | CHUK (0.31) | — | |
| SCHEMBL101210 | 0.70 | JAK2 (0.33) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.